Gain Therapeutics Inc expected to post a loss of 31  cents a share - Earnings Preview

Gain Therapeutics

05/08/2022 12:44

* Gain Therapeutics Inc  GANX.OQ   GANX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 9
(estimated). 
    * The Bethesda Maryland-based  company is expected to report
 a
69.3% decrease in revenue to $27.33 thousand from $89 thousand a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Gain Therapeutics
Inc is
for a loss of 31 cents per share. For the same quarter last
year, the company reported a loss of 30 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gain
Therapeutics
Inc is $21​, above​ its last closing price of $3.97. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.37       -0.37      -0.28     Beat    23.8
 Dec. 31 2022              -0.49      -0.32     Beat    34.2
 Sep. 30 2021  -0.36       -0.36      -0.39     Missed  -9.3​
 Jun. 30 2021  -0.31       -0.30      -0.30     Met     1.6
 ​​Mar.        -0.21       -0.21      -0.50     Missed  -132.6
 31 2021                                                
                                                        ​
 This summary was machine generated August 5 at 11:44 GMT.  All
figures in US dollars  unless otherwise stated